GLP-1 Drugs and Tuberculosis Risk in People With Type 2 Diabetes
A new study published in Nature Communications is putting a widely used class of diabetes medicines under the microscope, asking ...
A new study published in Nature Communications is putting a widely used class of diabetes medicines under the microscope, asking ...
For decades, obesity medicines were judged largely by how effectively they reduced appetite. Many could help people lose weight, but ...
Generic semaglutide is starting to rewrite the economics of type 2 diabetes care in Canada. A new analysis published in ...
Glucagon-like peptide-1 (GLP-1) receptor agonists—widely prescribed for type 2 diabetes and obesity—may carry a small but clinically important safety signal, ...
Newly Expanded FDA Approval Spurs Significant Uptake in Medicare Coverage of Wegovy for Cardiovascular Risk Reduction Following a pivotal FDA ...
A recent large-scale cohort study sheds new light on the psychiatric safety profile of glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely ...
Obesity treatment has entered a transformative era with the rise of incretin-based therapies (IBTs), notably GLP-1 receptor agonists, which have ...
A groundbreaking cohort study published recently in JAMA Network Open has revealed a promising therapeutic strategy to mitigate the risk ...
Recent advancements in the field of addiction medicine have positioned GLP-1 receptor agonists as a promising therapeutic option for individuals ...
In a groundbreaking advancement at the intersection of endocrinology and neurology, a recent phase 2 randomized trial has unveiled promising ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine